<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33607">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02097719</url>
  </required_header>
  <id_info>
    <org_study_id>GMA-LUM-12-022</org_study_id>
    <nct_id>NCT02097719</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This efficacy and safety study will evaluate LUMIGAN® .01 (bimatoprost 0.01%) alone compared
      to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL GFS, 0.5% (timolol 0.5% ophthalmic gel
      forming solution) in patients who require IOP lowering therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP) in the Study Eye</measure>
    <time_frame>Month 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>bimatoprost 0.01% and hypromellose 0.3%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>travoprost 0.004% and timolol 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost 0.01%</intervention_name>
    <description>Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.</description>
    <arm_group_label>bimatoprost 0.01% and hypromellose 0.3%</arm_group_label>
    <other_name>Lumigan® RC</other_name>
    <other_name>Lumigan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>travoprost 0.004%</intervention_name>
    <description>Travoprost 0.004% administered to both eyes once daily for 12 weeks.</description>
    <arm_group_label>travoprost 0.004% and timolol 0.5%</arm_group_label>
    <other_name>Travatan Z®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>timolol 0.5%</intervention_name>
    <description>Timolol 0.5% administered to both eyes once daily for 12 weeks.</description>
    <arm_group_label>travoprost 0.004% and timolol 0.5%</arm_group_label>
    <other_name>Timolol Maleate-EX</other_name>
    <other_name>Timolol GFS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hypromellose 0.3%</intervention_name>
    <description>Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.</description>
    <arm_group_label>bimatoprost 0.01% and hypromellose 0.3%</arm_group_label>
    <other_name>GenTeal®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ocular hypertension or glaucoma that requires treatment with medication

          -  Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes

        Exclusion Criteria:

          -  History of LASIK, LASEK, RK, and/or PRK in the study eye(s)

          -  History of any intraocular surgery or glaucoma laser surgery in the study eye(s)
             within 3 months

          -  Use of topical, periorbital, intravitreal or systemic steroid within 3 months or
             expected use during the course of study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Cloprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
